Real-World Experience Study of Elagolix For the Treatment of Endometriosis in Canada

NCT04080856 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-09-28

No results posted yet for this study

Summary

The objective of this study is to evaluate real-world effectiveness of elagolix in Canadian women with endometriosis.

Conditions

  • Endometriosis

Sponsors & Collaborators

Principal Investigators

  • ABBVIE INC. · AbbVie

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-04
Primary Completion
2021-09-27
Completion
2021-09-27

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04080856 on ClinicalTrials.gov